Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2021-09-21, Stock:ABBV, The news for the past five days is as follows:
2021-09-14: NEWS1: AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know.NEWS2: AbbVie Selloff Overdone, Stock Remains Undervalued: BMO.NEWS3: REGENXBIO (RGNX) Stock Up on Collaboration Deal With AbbVie.NEWS4: AbbVie (ABBV) to Co-Develop Regenxbio Eye Disease Gene Therapy.NEWS5: 5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal.NEWS6: REGENXBIO (RGNX) Moves 31.2% Higher: Will This Strength Last?.
2021-09-15: NEWS1: Is AbbVie's 4.9% Dividend Yield Safe?.
2021-09-16: NEWS1: AbbVie Submits Upadacitinib Applications In US, Europe For Ulcerative Colitis.NEWS2: 2 Embarrassingly Cheap Dividend Stocks to Buy.NEWS3: AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis.
2021-09-17: NEWS1: Why BeiGene's Shares Jumped on Friday.NEWS2: AbbVie Slumps On New FDA Order For Arthritis Drug — Is It A Buy Or A Sell?.NEWS3: AbbVie (ABBV) Files for Rinvoq in Ulcerative Colitis in US & EU.NEWS4: Pharma Stock Roundup: ABBV's Deal With RGNX, LLY COVID Drug's Government Order Win.
2021-09-20: NEWS1: AbbVie (ABBV) Stock Moves -1.23%: What You Should Know.NEWS2: AbbVie Submits Regulatory Application to FDA for Risankizumab-rzaa (SKYRIZI®) for the Treatment of Patients 16 Years and Older with Moderate to Severe Crohn's Disease.

Answer: Rise